Reversed effect of valproic acid on transcription inhibition of AML1-ETO fusion protein of kasumi-1 leukemic cell line.
- Author:
Lei ZHAO
1
;
Cui-Min ZHU
;
Zhi-Hua ZHANG
;
Wen-Liang TIAN
;
Chang-Lai HAO
Author Information
1. Department of Hematology, Affiliated Hospital of Chengde Medical Collge, Chengde 067000, Hebei Province, China.
- Publication Type:Journal Article
- MeSH:
Acetylation;
drug effects;
Cell Line, Tumor;
Core Binding Factor Alpha 2 Subunit;
drug effects;
genetics;
Cyclin D2;
genetics;
Gene Expression Regulation, Leukemic;
Histone Deacetylase Inhibitors;
pharmacology;
Histones;
drug effects;
Humans;
Oncogene Proteins, Fusion;
drug effects;
genetics;
RUNX1 Translocation Partner 1 Protein;
Valproic Acid;
pharmacology
- From:
Journal of Experimental Hematology
2009;17(2):363-367
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the mechanism of histone deacetylase (HDAC) inhibitor, valproic acid (VPA), reversing transcription inhibition of AML1-ETO fusion protein in Kasumi-1 cell line. The mRNA expressions of AML1-ETO, AML1 and cyclin D2 were detected by semi-quantitation RT-PCR after treating kasumi-1 cells with VPA at different doses/and different time points. The results indicated that the mRNA expression of AML1-ETO showed no obvious change, when kasumi-1 cells were treated with VPA. Compared with control group, the expression level of AML1 mRNA significantly increased in a dose-dependent manner. Compared with control group, the expression level of cyclin D2 mRNA significantly decreased when kasumi-1 cells had been treated with 3 mmol/L VPA as well as kasumi-1 cells were treated with different concentrations of VPA for 3 days. In conclusion, VPA could remove transcription inhibition of AML1-ETO fusion protein, increase transcription of AML1 and down-regulate mRNA expression of AML1 target gene cyclin D2 through HDAC inhibiting activity.
